MAPT and Alzheimer disease: Trajectories of DAPs in modules 2 and 5 were integrated with key markers of AD, such as CSF Aβ42/Aβ40, CSF p-tau181, tau-PET, neurodegeneration (measured with cortical thickness) and cognition (measured with the Mini-Mental State Examination (MMSE)) along the AD pseudotime (Fig. 6f).